But maybe we can spend a few minutes, Kevin and Andy, talking about the clinical value that you're, you're putting out there and that maybe Kevin has seen.

Yeah.

Thanks for us.

Thanks for, uh, inviting me to the call.

Um, I guess, you know, you'd mentioned you're maybe not so tech-forward when it comes to, you know, your, your practice and everything.

And I, I'm in the same boat.

And so when I hear Andy talking about all these things, it kind of, my eyes glaze over a little bit.

Yes.

And so we can really use it anywhere in the treatment algorithm.

You know, I'll tell you something that, uh, uh, let's call it a pearl, all right? So I impl-- Someone told me to do this.

I, I wish I could give credit to whoever did this.

But, um, I started getting my technicians, anyone on a glaucoma drop, I started them asking three questions, um, every visit.

And that was how many drops you miss per week, um, are you having any cost barriers with the drops, and then of course the discomfort, dry eye kinda questions that go along with it.

And just them putting that in the chart is, well, it's, you know, good documentation if we end up doing something obviously.

But even more important than that, it's kind of a reminder for me 'cause, you know, sometimes I'll forget and say, you know, "How many drops you missing?" But jeez, the, the patients are pr- a little more honest than I thought.

But what about Medicare Advantage? Have you guys had any experience with Medicare Advantage patients at all?

With an eye on the future, Kevin Talbot is the head of the Nuffield Department of Clinical Neuroscience at the University of Oxford.

So I think in the last couple of decades, our understanding of the fundamental causes and mechanisms of a disease has been transformed, largely through genetics, because we've been able to identify a range of genes, which if they are altered, so an error is in the gene, that can either increase the risk of motion neurone disease or even be the principal cause.

And while this may only affect a minority of people, What it does is it gives you a window into the biological factors that are driving the disease and causing it.

So if you know that a particular gene, if you have an error in it, a genetic mutation, that that can increase the risk of motion error and disease, it immediately tells you, what does that gene do? You say, well, it is involved in a particular pathway in the cell.

So therefore, that pathway becomes an immediate indicator.

area of interest for discovering drugs.

And that is something that has completely transformed our understanding of the disease because we've moved away just from looking down a microscope and saying something's wrong and there's a cell that's dying or there's a cell that's accumulating some kind of abnormal protein, which is an observation.

So they die of something else before they even get this.